Contextualizing the Clinical Journey of Belantamab Mafodotin as a BCMA Targeting ADC in Treatment of Relapsed or Refractory Multiple Myeloma
Time: 4:30 pm
day: Day Two PM
Details:
- Exploring preclinical evidence of Belantamab Mafodotin’s underlying mechanism of action in support of monotherapy development and rationale for synergy in combination
- Breaking down the clinical journey from statistically negative DREAMM-3 monotherapy readout to positive combination therapy data with DREAMM-7 and DREAMM-8
- Explaining the regulatory vs. clinical journey to better understand strength of evidence of Belantamab Mafodotin as a monotherapy and in combinations
